The effects of dipeptidyl peptidase-4 inhibitors in treatment of obese patients with type 2 diabetes
| Autor: | Jozo Coric, Amela Dizdarevic-Bostandzic, Zelija Velija-Asimi, Jasenko Karamehic, Amra Macic-Dzankovic, Sebija Izetbegovic, Jasminka Djelilovic-Vranic, Mirsad Panjeta |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Blood Glucose Male medicine.medical_specialty Incretin Blood Pressure Type 2 diabetes Sitagliptin Phosphate Body Mass Index Insulin resistance Internal medicine Diabetes mellitus medicine Humans Hypoglycemic Agents Obesity Triglycerides Aged Glycated Hemoglobin Dipeptidyl-Peptidase IV Inhibitors business.industry Body Weight Type 2 Diabetes Mellitus General Medicine Cholesterol LDL Middle Aged Triazoles medicine.disease Metformin Endocrinology Treatment Outcome Diabetes Mellitus Type 2 Sitagliptin Pyrazines Drug Therapy Combination Female Insulin Resistance business medicine.drug |
| Zdroj: | Medical archives (Sarajevo, Bosnia and Herzegovina). 67(5) |
| ISSN: | 0350-199X |
| Popis: | Introduction: Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of antihyperglycemic drugs that block degradation of incretin hormones. Goal: To assess the effects of treatment with DPP-4 inhibitors on glucoregulation and body weight in obese patients with type 2 diabetes mellitus. Patients and methods: The study included 9 females and 9 males with type 2 diabetes (n=18), BMI=31.24±2,26 kg/m2, mean age 58 ±6,8 years. The patients have been thoroughly evaluated before treatment, and 6 months after treatment with DPP-4 inhibitor (sitagliptin) in combination with metformin. Results: After 6 months of treatment with DPP-4 inhibitors in combination with metformin HbAlc (-1,49%)., FBG (-3.75 mmol/L) and PBG (-5.79 mmol/L) significantly reduced (p=0.000). Mean body weight also significantly reduced (-12.5%; p=0.000). Reduction of mean fasting insulin was 5.46 mIU/L or 27% (p=0.000). Mean HOMA-IR change was −1.64 (p=0.000). Also there was significant decreasing of systolic blood pressure (p=0.001), cholesterol (p=0.004), triglycerides (p=0.001), LDL (p=0.002) and increasing of HDL (p=0.002). Hypoglycaemia was not registered in any of the patients. Conclusion: These results show that in obese patients with type 2 diabetes, DPP-4 inhibitors treatment in combination with metformin was associated with improvements in glycaemic control, and a reduction in body weight. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|